ResearcherAmsterdam University Medical CentersActive in the last 2 years
Camilla Pecoraro
Matched on ORCID iD 0000-0002-6854-0551; OpenAlex author ID A5026579008. Sources: OpenAlex.
Their work
- Papers
- 15 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2021: 5 papers · 2022: none · 2023: 3 papers · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper
Papers 15
- 3-amino-1,2,4-triazine scaffolds as next-generation PDK inhibitors: Design, mechanistic insights, and efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejmech.2026.119202↗
- Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models. Co-author DOI 10.1002/cmdc.202500448↗
- Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer activity in pancreatic c… Co-author DOI 10.1016/j.bioorg.2024.107995↗
- New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/md23080327↗
- Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer activity in pancreatic cancer models. Co-author DOI 10.1016/j.bioorg.2024.107959↗
- Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, … Co-author DOI 10.1080/1061186x.2024.2385557↗
- Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.4155/fmc-2023-0234↗
- Discovery of the 3-Amino-1,2,4-triazine-Based Library as Selective PDK1 Inhibitors with Therapeutic Potential in Highly Aggressive Pancreatic Ductal Adenocarci… Co-author DOI 10.3390/ijms24043679↗
- Structural Manipulations of Marine Natural Products Inspire a New Library of 3-Amino-1,2,4-Triazine PDK Inhibitors Endowed with Antitumor Activity in Pancreati… Co-author DOI 10.3390/md21050288↗
- 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Nortopsentin Derivatives against Pancreatic Ductal Adenocarcinoma: Synthesis, Cytotoxic Activity, and Inhibition of CDK1. First author DOI 10.3390/md21070412↗
- 1,2,4-Oxadiazole Topsentin Analogs with Antiproliferative Activity against Pancreatic Cancer Cells, Targeting GSK3β Kinase. Co-author DOI 10.1002/cmdc.202000752↗
- GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.drup.2021.100779↗
- SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance. Co-author DOI 10.20517/cdr.2021.61↗
- Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). First author DOI 10.3390/cancers13174389↗
- A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells. Co-author DOI 10.3390/molecules27010019↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daniela Carbone · 15 shared papers, 2021–2026 · strength 2.86
- Paper 3-amino-1,2,4-triazine scaffolds as next-generation PDK inhibitors: Design, mechanistic insights, and efficacy in pancr… DOI 10.1016/j.ejmech.2026.119202↗
- Paper New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. DOI 10.3390/md23080327↗
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Patrizia Diana · 15 shared papers, 2021–2026 · strength 2.86
- Paper 3-amino-1,2,4-triazine scaffolds as next-generation PDK inhibitors: Design, mechanistic insights, and efficacy in pancr… DOI 10.1016/j.ejmech.2026.119202↗
- Paper New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. DOI 10.3390/md23080327↗
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Barbara Parrino · 13 shared papers, 2021–2026 · strength 2.58
- Paper 3-amino-1,2,4-triazine scaffolds as next-generation PDK inhibitors: Design, mechanistic insights, and efficacy in pancr… DOI 10.1016/j.ejmech.2026.119202↗
- Paper New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. DOI 10.3390/md23080327↗
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Elisa Giovannetti · 12 shared papers, 2021–2025 · strength 2.25
- Paper New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. DOI 10.3390/md23080327↗
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic D… DOI 10.1002/cmdc.202500448↗
- Stella Cascioferro · 11 shared papers, 2021–2025 · strength 2.03
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic D… DOI 10.1002/cmdc.202500448↗
- Paper Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic duc… DOI 10.4155/fmc-2023-0234↗
- Geng Xu · 5 shared papers, 2023–2025 · strength 1.09
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic D… DOI 10.1002/cmdc.202500448↗
- Paper Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer … DOI 10.1016/j.bioorg.2024.107959↗
- Fabio Scianò · 4 shared papers, 2024–2025 · strength 0.90
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic duc… DOI 10.4155/fmc-2023-0234↗
- Paper Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer … DOI 10.1016/j.bioorg.2024.107959↗
- Godefridus J. Peters · 5 shared papers, 2021–2025 · strength 0.77
- Paper Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic D… DOI 10.1002/cmdc.202500448↗
- Paper GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer. DOI 10.1016/j.drup.2021.100779↗
- Paper Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (… DOI 10.3390/cancers13174389↗
- Juan Deng · 2 shared papers, 2024–2025 · strength 0.47
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer … DOI 10.1016/j.bioorg.2024.107959↗
- Amir Avan · 2 shared papers, 2021 · strength 0.27
- Paper Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (… DOI 10.3390/cancers13174389↗
- Paper A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects… DOI 10.3390/molecules27010019↗
- Mahrou Vahabi · 1 shared paper, 2025 · strength 0.27
- Giulia Lencioni · 1 shared paper, 2025 · strength 0.27
- Cecilia Bergonzini · 1 shared paper, 2024 · strength 0.20
- Rosa Wijnen · 1 shared paper, 2021 · strength 0.14
- Amir Avan · 1 shared paper, 2021 · strength 0.12
- Ornella Randazzo · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.